Side-by-side · Research reference
BPC-157vsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed9/53 cited
BAnimal-StrongDraft13/39 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
BPC-157
KPV
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
No known endogenous receptor; mechanism still under investigation
No melanocortin receptor binding
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
KPV
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
200–500 mcg / day SQ or oralDalle-Pang 2024
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
Daily or 2–3× per week
Lower / starter dose
200 mcg / day
Conservative starter for new users.
100 mcg / day
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
4–8 weeks per cycle
Reconstitution
Bacteriostatic water, 1–2 mL
Bacteriostatic water (SQ form)
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
No specific time; often taken with / before meals (oral)
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
Hours (estimated; rapid tissue uptake)
04Side Effects & Safety
Parameter
BPC-157
KPV
Injection site reaction
Mild irritation (anecdotal)
Mild irritation
GI symptoms
None reported in PL-14736 Phase 2
Rare nausea (oral form)
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid — insufficient data
Long-term safety
Unknown beyond Phase 2 trial duration
Limited human data
Drug interactions
None established
—
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
BPC-157
KPV
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
29–31G insulin syringe (SQ form).
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions